ClinicalTrials.gg
CompletedNCT01308567FIRSTANAUpdated Jun 5, 2019Results posted

Cabazitaxel Versus Docetaxel Both With Prednisone in Patients With Metastatic Castration Resistant Prostate Cancer

A Phase 3 interventional study of Cabazitaxel (XRP6258) and Docetaxel (XRP6976) in Prostate Cancer, sponsored by Sanofi. Completed at 167 sites in 25 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2019-06-05.

Sponsored by Sanofi · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,168
Allocation
Randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 46 studies testing cabazitaxel in Prostatic Neoplasms — 6 open to participants now, 10 under way, none of them phase 3. cabazitaxel · Prostatic Neoplasms.

Enrollment
2nd of 46
1,168 · median 60
Started
2011
with 4 others
Phase 3
7 of 46
none open now
Registered
3rd of 46
by date
Lead sponsor
10 of 46
Sanofi

Among the 46 studies testing cabazitaxel in Prostatic Neoplasms, this one is the 2nd largest by enrollment, is one of 5 that started in 2011, is one of 7 in phase 3, and was the 3rd registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,579 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

6 of the 46 studies testing cabazitaxel in Prostatic Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About cabazitaxel

cabazitaxel: first FDA approval 2010 (JEVTANA KIT), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,228 Prostatic Neoplasms studies recruiting now, 927 (75%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies testing cabazitaxel in Prostatic Neoplasms, or all of them as a file.
02

Study summary

Primary Objective:

  • To demonstrate the superiority of cabazitaxel plus prednisone at 25 mg/m\^2 (Arm A) or 20 mg/m\^2 (Arm B) versus docetaxel plus prednisone (Arm C) in term of overall survival (OS) in participants with metastatic castration resistant prostate cancer (mCRPC) and not previously treated with chemotherapy.

Secondary Objectives:

  • To evaluate safety in the 3 treatment arms.
  • To compare efficacy of cabazitaxel at 20 mg/m\^2 and 25 mg/m\^2 to docetaxel for:

    • Progression Free Survival (PFS) (RECIST 1.1)
    • Tumor progression free survival (RECIST 1.1)
    • Tumor response in participants with measurable disease (RECIST 1.1),
    • PSA response
    • PSA-Progression free survival (PSA-PFS).
    • Pain response in participants with stable pain at baseline
    • Pain progression free survival
    • Time to occurrence of any skeletal related events (SRE)
  • To compare Health-Related Quality of Life (HRQL).
  • To assess the pharmacokinetics and pharmacogenomics of cabazitaxel.
Read the detailed description

Participants were treated until progressive disease, unacceptable toxicity, or participant's refusal of further study treatment. All participants were followed when on study treatment and after completion of study treatment during follow up period until death or the study cutoff date, whichever comes first.

03

Conditions studied

  • Prostate Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • I 01. - or cytologically-confirmed prostate adenocarcinoma.
  • I 02. disease.
  • I 03. Progressive disease while receiving hormonal therapy or after surgical castration.
  • I 04. Effective castration (serum testosterone levels ≤0.50 ng/mL) by orchiectomy and/or luteinizing hormone-releasing hormone (LHRH) agonists or antagonist with or without anti-androgens.

Exclusion criteria

Exclusion criteria:

  • E 01. Prior chemotherapy for prostate cancer,
  • E 02. Less than 28 days elapsed from prior treatment with estramustine, radiotherapy or surgery to the time of randomization. Participants on biphosphonates prior to study entry.
  • E 03. Prior isotope therapy, whole pelvic radiotherapy, or radiotherapy to >30% of bone marrow.
  • E 04. Adverse events (excluding alopecia and those listed in the specific exclusion criteria) from any prior anticancer therapy of grade >1(National Cancer Institute Common Terminology Criteria [] v4.03) at the time of randomization.
  • E 05. Less than 18 years (or country's legal age of majority if the legal age is >18 years).
  • E 06. (ECOG) performance status >2.
  • E 07. History of , uncontrolled spinal cord compression, or carcinomatous meningitis or new evidence of brain or .
  • E 08. Prior .
  • E 09. Participation in another clinical trial and any concurrent treatment with any drug within 30 days prior to randomization.
  • E 10. Any of the following within 6 months prior to study enrollment: myocardial infarction, severe/unstable angina pectoris, coronary/peripheral artery bypass graft, (NYHA) class III or IV congestive heart failure, stroke or .
  • E 11. Any of the following within 3 months prior to randomization: treatment resistant peptic ulcer disease, erosive esophagitis or gastritis, infectious or inflammatory bowel disease, diverticulitis, pulmonary embolism, or other uncontrolled thromboembolic event.
  • E 12. Acquired immunodeficiency syndrome (AIDS-related illnesses) or known disease requiring antiretroviral treatment.
  • E 13. Any severe acute or chronic medical condition which could impair the ability of the participant to participate to the study or interfere with interpretation of study results, or participants unable to comply with the study procedures.
  • E 14. Absence of signed and dated Institutional Review Board (IRB)-approved participant form prior to enrollment into the study.
  • E 15. Participants with who did not agree to use accepted and effective method of during the study treatment period.
  • E 16. History of to docetaxel, or polysorbate 80.
  • E 17. Inadequate organ and bone marrow function
  • E 18. to the use of treatment.
  • E 19. Symptomatic peripheral neuropathy grade >2 (National Cancer Institute Common Terminology Criteria [NCI CTCAE] v.4.03).

The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.

Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,168 participants (actual)

Study arms

  • Experimental
    Cabazitaxel 25 mg/m^2

    Cabazitaxel 25 mg/m\^2 intravenous (IV) infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until disease progression (DP), unacceptable toxicity or participant's refusal.

    Drug: Cabazitaxel (XRP6258) · Drug: Prednisone

  • Experimental
    Cabazitaxel 20 mg/m^2

    Cabazitaxel 20 mg/m\^2 IV infusion on Day 1 of each 21 -day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.

    Drug: Cabazitaxel (XRP6258) · Drug: Prednisone

  • Active comparator
    Docetaxel 75 mg/m^2

    Docetaxel (TXT) 75 mg/m\^2 IV infusion on Day 1 of each 21-day cycle in combination with Prednisone 10 mg orally, once daily until DP, unacceptable toxicity or participant's refusal.

    Drug: Docetaxel (XRP6976) · Drug: Prednisone

Interventions

  • Pharmaceutical form: Solution for injection; Route of administration: Intravenous

  • Pharmaceutical form: Solution for injection'; Route of administration: Intravenous

  • Pharmaceutical form: Tablet; Route of administration: Oral

06

What researchers measure

Primary outcomes

  1. Overall Survival (OS)

    OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )

Secondary outcomes

  1. Progression Free Survival (PFS)

    PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)

  2. Time to Tumor Progression Free Survival

    Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)

  3. Percentage of Participants With Overall Objective Tumor Response

    Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

    Time frame: Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)

  4. Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)

    Time to PSA-PFS: time interval between date of randomization \& first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA \<10 ng/mL):(a)in participants with baseline PSA\>0 ng/mL\&\<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.

    Time frame: Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)

  5. Percentage of Participants With PSA Response

    PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.

    Time frame: Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)

  6. Time to Pain Progression Free Survival (Pain PFS)

    Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)

  7. Percentage of Participants With Pain Response

    Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.

    Time frame: Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)

  8. Skeletal Related Events (SRE) Free Survival

    SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.

    Time frame: Baseline until occurrence of first SRE or death (maximum duration: 51 months)

  9. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)

    FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.

    Time frame: Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)

  10. Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL

    FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.

    Time frame: Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)

07

Results

Posted Mar 3, 2017

Participant flow

The study was conducted at 159 centers in 25 countries. A total of 1510 participants were screened between 17 May 2011 and 09 September 2015 of whom 1168 participants were randomized and 342 were considered as screen failures.

Participant flow — Overall Study
MilestoneDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Started391389388
Treated388382377
Completed389385384
Not completed244
Withdrew: Lost to follow-up244

Outcome measures

PrimaryOverall Survival (OS)

OS was defined as the time interval from the date of randomization to the date of death due to any cause. In the absence of confirmation of death, survival time was censored at the last date participant was known to be alive, or at the cut-off date if the participant's last contact was after the cut-off date. The study cut-off date for the final analysis of OS was the date when the 774th death had been observed. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline up to death or study cut-off date, whichever was earlier (maximum duration: 51 months )
Reported as:
Median · months
Overall Survival (OS)
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Overall Survival (OS)24.3 (22.18 to 27.60)24.5 (21.75 to 27.20)25.2 (22.90 to 26.97)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Log Rank · p = 0.7574 (P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479) · Hazard ratio (hr): 0.975 · 95% CI 0.819 to 1.16Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Log Rank · p = 0.9967 (P-value from two-sided stratified log-rank test, stratified for ECOG PS score at baseline, measurable disease at baseline and region with commercial availability of cabazitaxel at time of randomization. Threshold for statistical significance = 0.0479) · Hazard ratio (hr): 1.009 · 95% CI 0.85 to 1.197Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryProgression Free Survival (PFS)

PFS: time interval between date of randomization to date of first occurrence of any of following events: tumor progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1; Prostate Specific Antigen (PSA) progression; pain progression or death due to any cause. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline up to tumor progression, PSA progression, pain progression or death (maximum duration: 51 months)
Reported as:
Median · months
Progression Free Survival (PFS)
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Progression Free Survival (PFS)5.3 (4.86 to 5.78)4.4 (3.91 to 5.09)5.1 (4.60 to 5.72)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 0.989 · 95% CI 0.849 to 1.152Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Hazard ratio (hr): 1.063 · 95% CI 0.913 to 1.236Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryTime to Tumor Progression Free Survival

Time to tumor progression free survival was defined as the time interval between randomization and the date of first occurrence of tumor progression (assessed using RECIST version 1.1) or death, whichever was earlier. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline up to tumor progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Reported as:
Median · months
Time to Tumor Progression Free Survival
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Tumor Progression Free Survival12.1 (11.30 to 13.77)13.4 (11.37 to 14.75)13.1 (11.66 to 14.32)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 0.958 · 95% CI 0.785 to 1.17Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Hazard ratio (hr): 0.916 · 95% CI 0.75 to 1.118Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryPercentage of Participants With Overall Objective Tumor Response

Overall objective tumor response was defined as having a partial response (PR) or complete response (CR) according to the RECIST version 1.1. CR was defined as disappearance of all target and non-target lesions and normalization of tumor marker level. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm. PR was defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.

Time frame:
Baseline up to DP or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Overall Objective Tumor Response
percentage of participantsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With Overall Objective Tumor Response30.9 (24.0 to 37.7)32.4 (25.8 to 39.1)41.6 (34.3 to 49.0)
SecondaryTime to Prostate Serum Antigen Progression Free Survival (PSA-PFS)

Time to PSA-PFS: time interval between date of randomization \& first occurrence of PSA progression/ death, whichever was earlier. PSA progression:1) In PSA responders(≥50% decline from baseline PSA of ≥10 ng/mL):increase of ≥25%(at least 2 ng/mL)over nadir value, confirmed by second PSA value at least 3 weeks later;2)In PSA non-responders(not achieved ≥50% decline from baseline PSA ≥10 ng/mL):increase of ≥25% (at least 2 ng/mL) over baseline value, confirmed by second PSA value at least 3 weeks later;3)In participants not eligible for PSA response(baseline PSA \<10 ng/mL):(a)in participants with baseline PSA\>0 ng/mL\&\<10 ng/mL: increase in PSA by 25% (at least 2 ng/mL) above baseline level, confirmed by second PSA value at least 3weeks apart;(b)in participants with baseline value=0ng/mL: a post baseline PSA value ≥2ng/mL.Early rise in PSA only indicated progression if it was associated with another sign of DP or if it continued beyond 12 weeks. Analysis performed by Kaplan-Meier method.

Time frame:
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Reported as:
Median · months
Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Prostate Serum Antigen Progression Free Survival (PSA-PFS)8.3 (7.66 to 9.20)8.2 (7.43 to 8.90)9.2 (8.44 to 9.92)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 0.948 · 95% CI 0.8 to 1.123Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Hazard ratio (hr): 1.047 · 95% CI 0.886 to 1.238Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryPercentage of Participants With PSA Response

PSA response was defined as ≥50% decrease from baseline in serum PSA levels, confirmed by a second PSA value at least 3 weeks later in participants with baseline PSA value ≥10 ng/mL.

Time frame:
Baseline up to PSA progression or death due to any cause or study cut-off date, whichever was earlier (maximum duration: 51 months)
Reported as:
Number · percentage of participants
Percentage of Participants With PSA Response
percentage of participantsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With PSA Response68.4 (63.5 to 73.2)60.7 (55.5 to 65.8)68.7 (63.8 to 73.6)
SecondaryTime to Pain Progression Free Survival (Pain PFS)

Time to pain PFS was defined as the time interval between date of randomization and the date of the first occurrence of pain progression or death, whichever was earlier. Pain progression was defined as an increase of ≥1 point in the median present pain intensity (PPI) score from the nadir confirmed by a second assessment at least 3 weeks later or ≥25 % increase in the mean analgesic score from baseline, due to cancer related pain confirmed by a second assessment at least 3 weeks later or requirement for local palliative radiotherapy. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline until disease progression, death or study cut-off date (maximum duration: 51 months)
Reported as:
Median · months
Time to Pain Progression Free Survival (Pain PFS)
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Time to Pain Progression Free Survival (Pain PFS)10.1 (8.28 to 11.76)8.0 (6.90 to 9.66)7.3 (6.44 to 9.30)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.189 · 95% CI 0.986 to 1.434Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Hazard ratio (hr): 1.189 · 95% CI 0.985 to 1.435Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryPercentage of Participants With Pain Response

Pain response was defined as either a ≥2-point decrease from baseline median PPI score without increase in analgesic score, or a ≥50% decrease in analgesic use from baseline mean analgesic score (only in participants with baseline mean analgesic score≥10) without increase in the pain. Either criterion was maintained for 2 consecutive evaluations at least 3 weeks apart. PPI was rated by participant in a diary using a scale of 0=no pain, 1=mild, 2=discomforting, 3=distressing, 4=horrible 5=excruciating. Analgesic use was recorded by the participant in a diary. Analgesic score was calculated from the analgesic use data based on a table of analgesic medications, with non-narcotic medications assigned a value of 1 point and narcotic medications assigned a value of 4 points.

Time frame:
Baseline until pain progression, death or study cut-off date (maximum duration: 51 months)
Reported as:
Number · percentage of participants
Percentage of Participants With Pain Response
percentage of participantsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Percentage of Participants With Pain Response40.7 (30.0 to 51.4)42.4 (32.7 to 52.2)39.4 (30.0 to 48.8)
SecondarySkeletal Related Events (SRE) Free Survival

SRE free survival was defined as the time interval between the date of randomization and the date of the occurrence of the first event defining a SRE or death due to any cause, whichever was earlier. SRE were assessed by clinical evaluation. Occurrence of SRE was defined as: pathological fracture(s) and/or spinal cord compression; need for bone irradiation, including radioisotopes or bone surgery; and change of antineoplastic therapy (including introduction of bisphosphonates or denosumab in the setting of increased pain) to treat bone pain. Analysis was performed by Kaplan-Meier method.

Time frame:
Baseline until occurrence of first SRE or death (maximum duration: 51 months)
Reported as:
Median · months
Skeletal Related Events (SRE) Free Survival
monthsDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Skeletal Related Events (SRE) Free Survival19.0 (15.24 to 22.44)19.2 (15.21 to 24.61)17.1 (14.59 to 20.50)
Statistical analysis
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 25 mg/m^2 · Hazard ratio (hr): 1.121 · 95% CI 0.886 to 1.417Cabazitaxel 25 mg/m\^2 vs Docetaxel 75 mg/m\^2
  • Docetaxel 75 mg/m^2 vs Cabazitaxel 20 mg/m^2 · Hazard ratio (hr): 1.014 · 95% CI 0.798 to 1.288Cabazitaxel 20 mg/m\^2 vs Docetaxel 75 mg/m\^2
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)

FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). FACT-P total score was the sum of all 5 subscale scores. It ranged from 0 to156 with higher score indicated better quality of life with fewer symptoms.

Time frame:
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P) Total Score as a Measure of Health Related Quality of Life (HRQoL)
units on a scaleDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Change at Cycle 14.17 (1.3 to 7.05)7.66 (4.79 to 10.53)6.93 (3.97 to 9.88)
Change at Cycle 25.33 (2.46 to 8.2)7.15 (4.28 to 10.01)5.28 (2.32 to 8.24)
Change at Cycle 34.94 (2.06 to 7.82)6.79 (3.93 to 9.66)4.61 (1.64 to 7.58)
Change at Cycle 44.07 (1.17 to 6.96)5.22 (2.35 to 8.09)4.01 (1.03 to 6.99)
Change at Cycle 54.36 (1.44 to 7.27)5.16 (2.26 to 8.06)4.09 (1.09 to 7.08)
Change at Cycle 63.46 (0.53 to 6.39)3.8 (0.88 to 6.73)3.37 (0.35 to 6.39)
Change at Cycle 73.16 (0.2 to 6.12)3.66 (0.71 to 6.61)3.42 (0.38 to 6.45)
Change at Cycle 82.61 (-0.37 to 5.59)2.71 (-0.27 to 5.68)1.67 (-1.39 to 4.73)
Change at Cycle 92.2 (-0.87 to 5.27)2.67 (-0.35 to 5.68)1.89 (-1.22 to 5.01)
Change at Cycle 102.08 (-1.05 to 5.21)2.09 (-0.99 to 5.18)1.84 (-1.32 to 5)
Change at Cycle 110.15 (-3.18 to 3.47)3.35 (0.1 to 6.6)2.68 (-0.67 to 6.02)
Change at Cycle 120.52 (-2.94 to 3.97)3.95 (0.61 to 7.29)0.63 (-2.78 to 4.05)
Change at Cycle 131.79 (-1.94 to 5.53)2.48 (-0.95 to 5.91)0.55 (-3 to 4.09)
Change at Cycle 14-1.78 (-5.56 to 2)2.2 (-1.29 to 5.69)-0.42 (-4.06 to 3.21)
Change at Cycle 15-3.49 (-7.5 to 0.51)1.74 (-1.82 to 5.3)1.22 (-2.51 to 4.95)
Change at Cycle 16-3.83 (-7.89 to 0.23)1.62 (-2.11 to 5.35)0.5 (-3.3 to 4.3)
Change at Follow-up 1-1.08 (-4.15 to 1.99)-1.45 (-4.48 to 1.59)-1.82 (-4.97 to 1.32)
Change at Follow-up 2-0.02 (-3.16 to 3.13)-1.98 (-5.17 to 1.21)-1.78 (-5.04 to 1.47)
Change at Follow-up 3-0.55 (-3.83 to 2.74)-2.16 (-5.47 to 1.14)-2.68 (-6.08 to 0.72)
Change at Follow-up 4-1.19 (-4.61 to 2.23)-3.64 (-7.18 to -0.1)-1.7 (-5.25 to 1.84)
Change at Follow-up 5-2.05 (-5.61 to 1.51)-6.73 (-10.39 to -3.06)-0.6 (-4.18 to 2.99)
Change at Follow-up 6-1.17 (-4.92 to 2.58)-5.36 (-9.32 to -1.4)-4.05 (-7.87 to -0.23)
SecondaryChange From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL

FACT-P was a 39-item participant rated questionnaire that measures the concerns of participants with prostate cancer. It consisted of 5 sub-scales assessing physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and prostate-specific concerns (12 items). Physical well being, functional well being, and prostate-specific concerns sub-scales of the FACT-P questionnaire were combined to calculate TOI. Total TOI score ranges from 0 to 104, with higher scores representing a better quality of life with fewer symptoms.

Time frame:
Baseline, Day 1 of each cycle 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16 (each cycle 21-day); post-treatment follow up 1, 2, 3, 4, 5, 6 (each up to 12 weeks)
Reported as:
Least squares mean · units on a scale
Change From Baseline in Functional Assessment of Cancer Therapy-Prostate (FACT-P):Trial Outcome Index (TOI) as a Measure of HRQoL
units on a scaleDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Change at Cycle 13.31 (1.05 to 5.58)6.09 (3.83 to 8.35)5.76 (3.43 to 8.09)
Change at Cycle 24.37 (2.1 to 6.64)5.96 (3.7 to 8.21)4.26 (1.92 to 6.59)
Change at Cycle 34.31 (2.04 to 6.58)5.28 (3.02 to 7.53)3.65 (1.31 to 5.99)
Change at Cycle 43.39 (1.11 to 5.67)4.1 (1.83 to 6.36)3.2 (0.85 to 5.55)
Change at Cycle 53.41 (1.11 to 5.7)4.05 (1.76 to 6.34)3.1 (0.74 to 5.46)
Change at Cycle 62.76 (0.45 to 5.07)3.15 (0.85 to 5.46)2.88 (0.5 to 5.26)
Change at Cycle 72.29 (-0.05 to 4.62)3.14 (0.81 to 5.47)2.94 (0.54 to 5.34)
Change at Cycle 81.67 (-0.69 to 4.02)2.26 (-0.09 to 4.61)1.49 (-0.92 to 3.91)
Change at Cycle 91.75 (-0.67 to 4.18)2.15 (-0.24 to 4.53)1.73 (-0.73 to 4.19)
Change at Cycle 101.52 (-0.96 to 4)1.56 (-0.88 to 3.99)1.62 (-0.89 to 4.12)
Change at Cycle 110.35 (-2.29 to 3)2.72 (0.15 to 5.3)2.19 (-0.46 to 4.84)
Change at Cycle 121.04 (-1.7 to 3.79)3.08 (0.43 to 5.73)0.75 (-1.95 to 3.46)
Change at Cycle 132.13 (-0.85 to 5.11)1.78 (-0.94 to 4.5)0.82 (-1.98 to 3.62)
Change at Cycle 14-0.13 (-3.15 to 2.89)1.59 (-1.18 to 4.36)-0.07 (-2.95 to 2.81)
Change at Cycle 15-2.1 (-5.29 to 1.09)1.29 (-1.53 to 4.11)1.49 (-1.47 to 4.45)
Change at Cycle 16-2.26 (-5.49 to 0.97)1.23 (-1.73 to 4.19)1.44 (-1.59 to 4.47)
Change at Follow-up 1-0.96 (-3.38 to 1.47)-1.26 (-3.66 to 1.14)-1.62 (-4.11 to 0.86)
Change at Follow-up 2-0.07 (-2.56 to 2.42)-1.12 (-3.65 to 1.41)-1.05 (-3.62 to 1.53)
Change at Follow-up 3-0.32 (-2.92 to 2.28)-1.67 (-4.29 to 0.96)-1.98 (-4.68 to 0.72)
Change at Follow-up 4-0.91 (-3.62 to 1.8)-2.54 (-5.36 to 0.29)-1.03 (-3.84 to 1.78)
Change at Follow-up 5-2.15 (-4.99 to 0.69)-5.36 (-8.27 to -2.44)-0.82 (-3.67 to 2.02)
Change at Follow-up 6-1.77 (-4.75 to 1.2)-5.32 (-8.49 to -2.16)-2.76 (-5.82 to 0.3)

Adverse events

Collected over All Adverse Events (AE) were collected from signature of the informed consent form up to the final visit (up to 83 months) regardless of seriousness or relationship to investigational product.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Docetaxel 75 mg/m^2—126/387 (32.6%)353/387 (91.2%)
Cabazitaxel 20 mg/m^2—127/369 (34.4%)323/369 (87.5%)
Cabazitaxel 25 mg/m^2—188/391 (48.1%)354/391 (90.5%)
Most frequent serious events
Showing 10 of 250
Most frequent serious events
EventDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
Febrile neutropeniaBlood and lymphatic system disorders27/3877/36940/391
Neutropenic infectionInfections and infestations12/3873/36921/391
HaematuriaRenal and urinary disorders2/38710/36913/391
PneumoniaInfections and infestations8/3873/36912/391
NeutropeniaBlood and lymphatic system disorders4/3874/36910/391
DiarrhoeaGastrointestinal disorders4/3872/36910/391
Urinary tract infectionInfections and infestations2/3879/3698/391
Pulmonary embolismRespiratory, thoracic and mediastinal disorders3/3878/3699/391
AnaemiaBlood and lymphatic system disorders2/3878/3695/391
Urinary tract obstructionRenal and urinary disorders1/3876/3693/391
Most frequent other events
Showing 10 of 40
Most frequent other events
EventDocetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2
DiarrhoeaGastrointestinal disorders140/387120/369190/391
AlopeciaSkin and subcutaneous tissue disorders151/38733/36951/391
FatigueGeneral disorders110/387105/369126/391
NauseaGastrointestinal disorders86/38792/369125/391
Peripheral sensory neuropathyNervous system disorders97/38743/36948/391
ConstipationGastrointestinal disorders69/38790/36978/391
AstheniaGeneral disorders94/38784/36990/391
HaematuriaRenal and urinary disorders13/38769/36991/391
Oedema peripheralGeneral disorders78/38736/36930/391
VomitingGastrointestinal disorders44/38744/36975/391

Baseline characteristics

Age, Customized
Age, Customized(Participants)Docetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2Total
<65 years123128125376
65-74 years181187182550
≥75 years877481242
Sex: Female, Male
Sex: Female, Male(Participants)Docetaxel 75 mg/m^2Cabazitaxel 20 mg/m^2Cabazitaxel 25 mg/m^2Total
Female0000
Male3913893881168
08

Study locations

167 sites
  • Investigational Site Number 840004
    Muscle Shoals, Alabama 35661, United States
  • Investigational Site Number 840009
    Anaheim, California 92801, United States
  • Investigational Site Number 840014
    Bakersfield, California 93309, United States
  • Investigational Site Number 840030
    Sacramento, California 95816, United States
  • Investigational Site Number 840003
    San Bernardino, California 92404, United States
  • Investigational Site Number 840012
    San Francisco, California 94143, United States
  • Investigational Site Number 840019
    Denver, Colorado 80262, United States
  • Investigational Site Number 840013
    Boca Raton, Florida 33486, United States
  • Investigational Site Number 840035
    Jacksonville, Florida 32256, United States
  • Investigational Site Number 840001
    Port Saint Lucie, Florida 34952, United States
  • Investigational Site Number 840015
    Decatur, Illinois 62526, United States
  • Investigational Site Number 840018
    Wichita, Kansas 67214, United States
  • Investigational Site Number 840010
    Paducah, Kentucky 42002, United States
  • Investigational Site Number 840008
    New Orleans, Louisiana 70112, United States
  • Investigational Site Number 840006
    Rockville, Maryland 20850, United States
  • Investigational Site Number 840238
    Boston, Massachusetts 02114, United States
  • Investigational Site Number 840138
    Boston, Massachusetts 02115, United States
  • Investigational Site Number 840038
    Brookline, Massachusetts 02115, United States
  • Investigational Site Number 840005
    Detroit, Michigan 48202, United States
  • Investigational Site Number 840021
    Saint Louis Park, Minnesota 55416, United States
  • Investigational Site Number 840016
    Kansas City, Missouri 64128, United States
  • Investigational Site Number 840020
    Lincoln, Nebraska 68506, United States
  • Investigational Site Number 840017
    East Orange, New Jersey 07018, United States
  • Investigational Site Number 840033
    Albuquerque, New Mexico 87109, United States
  • Investigational Site Number 840036
    Raleigh, North Carolina 27607, United States
  • Investigational Site Number 840011
    Washington, North Carolina 27889, United States
  • Investigational Site Number 840026
    Akron, Ohio 44302, United States
  • Investigational Site Number 840023
    Cleveland, Ohio 44106, United States
  • Investigational Site Number 840032
    Dunmore, Pennsylvania 18512, United States
  • Investigational Site Number 840007
    Pawtucket, Rhode Island 02860, United States
  • Investigational Site Number 840037
    Myrtle Beach, South Carolina 29572, United States
  • Investigational Site Number 840028
    Chattanooga, Tennessee 37421, United States
  • Investigational Site Number 036016
    Bankstown, 2200, Australia
  • Investigational Site Number 036008
    Camperdown, 2050, Australia
  • Investigational Site Number 036015
    Coffs Harbour, 2450, Australia
  • Investigational Site Number 036001
    Concord, 2137, Australia
  • Investigational Site Number 036017
    Fitzroy, 3065, Australia
  • Investigational Site Number 036003
    Herston, 4029, Australia
  • Investigational Site Number 036010
    Hornsby, 2077, Australia
  • Investigational Site Number 036012
    Kurralta Park, 5037, Australia
  • Investigational Site Number 036002
    Parkville, 3050, Australia
  • Investigational Site Number 036009
    South Brisbane, 4101, Australia
  • Investigational Site Number 036011
    Subiaco, 6008, Australia
  • Investigational Site Number 036013
    Wodonga, 3690, Australia
  • Investigational Site Number 112001
    Minsk, 220013, Belarus
  • Investigational Site Number 112002
    Minsk, 223040, Belarus
  • Investigational Site Number 112004
    Vitebsk, 210603, Belarus
  • Investigational Site Number 076006
    Passo Fundo, 99010-260, Brazil
  • Investigational Site Number 076001
    Porto Alegre, 90035-001, Brazil
  • Investigational Site Number 076002
    Porto Alegre, 90610-000, Brazil
  • Investigational Site Number 076004
    Rio De Janeiro, 20230-130, Brazil
  • Investigational Site Number 076009
    Sao Jose Do Rio Preto, 15090-000, Brazil
  • Investigational Site Number 076005
    Sao Paulo, 01246-000, Brazil
  • Investigational Site Number 076003
    Uberlandia, 38408 150, Brazil
  • Investigational Site Number 124002
    London, N6A 4L6, Canada
  • Investigational Site Number 124007
    Mississauga, L5M 2N1, Canada
  • Investigational Site Number 124005
    Moncton, E1C 6Z8, Canada
  • Investigational Site Number 124003
    Montreal, H2L 4M1, Canada
  • Investigational Site Number 124004
    Quebec, G1R 2J6, Canada
  • Investigational Site Number 124006
    Toronto, M4N 3M5, Canada
  • Investigational Site Number 156005
    Beijing, 100034, China
  • Investigational Site Number 156002
    Shanghai, 200032, China
  • Investigational Site Number 156003
    Shanghai, 200040, China
  • Investigational Site Number 156004
    Shanghai, 200040, China
  • Investigational Site Number 203002
    Brno, 65653, Czechia
  • Investigational Site Number 203003
    Novy Jicin, 74101, Czechia
  • Investigational Site Number 203001
    Olomouc, 77520, Czechia
  • Investigational Site Number 203004
    Praha 2, 12808, Czechia
  • Investigational Site Number 208002
    Herlev, 2730, Denmark
  • Investigational Site Number 208001
    København Ø, 2100, Denmark
  • Investigational Site Number 208003
    Odense C, 5000, Denmark
  • Investigational Site Number 208004
    Ålborg, 9100, Denmark
  • Investigational Site Number 246002
    Helsinki, 00290, Finland
  • Investigational Site Number 246001
    Kuopio, 70210, Finland
  • Investigational Site Number 246003
    Turku, FIN-20520, Finland
  • Investigational Site Number 250010
    Besancon Cedex, 25030, France
  • Investigational Site Number 250002
    Bordeaux Cedex, 33076, France
  • Investigational Site Number 250006
    Caen Cedex 05, 14076, France
  • Investigational Site Number 250005
    Lyon, 69373, France
  • Investigational Site Number 250003
    Paris Cedex 05, 75231, France
  • Investigational Site Number 250004
    Paris Cedex 10, 75475, France
  • Investigational Site Number 250001
    Paris Cedex 15, 75908, France
  • Investigational Site Number 250007
    Poitiers Cedex, 86021, France
  • Investigational Site Number 250008
    Suresnes, 92151, France
  • Investigational Site Number 250009
    Villejuif, 94805, France
  • Investigational Site Number 276003
    Aachen, 52074, Germany
  • Investigational Site Number 276005
    Berlin, 14197, Germany
  • Investigational Site Number 276001
    Düsseldorf, 40225, Germany
  • Investigational Site Number 276004
    Erlangen, 91054, Germany
  • Investigational Site Number 276002
    Homburg, 66421, Germany
  • Investigational Site Number 276006
    München, 81675, Germany
  • Investigational Site Number 376004
    Kfar Saba, 44281, Israel
  • Investigational Site Number 376003
    Petah-Tikva, 49100, Israel
  • Investigational Site Number 376002
    Tel Aviv, 64239, Israel
  • Investigational Site Number 380001
    Arezzo, 06156, Italy
  • Investigational Site Number 380004
    Bari, 70124, Italy
  • Investigational Site Number 380003
    Orbassano, 10043, Italy
  • Investigational Site Number 380005
    Roma, 00144, Italy
  • Investigational Site Number 380002
    Trento, 38100, Italy
  • Investigational Site Number 392001
    Bunkyo-Ku, Japan

Showing the first 100 of 167 sites across 25 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Thiery-Vuillemin A, Fizazi K, Sartor O, Oudard S, Bury D, Thangavelu K, Ozatilgan A, Poole EM, Eisenberger M, de Bono J. An analysis of health-related quality of life in the phase III PROSELICA and FIRSTANA studies assessing cabazitaxel in patients with metastatic castration-resistant prostate cancer. ESMO Open. 2021 Apr;6(2):100089. doi: 10.1016/j.esmoop.2021.100089. Epub 2021 Mar 16. PubMed 33740734 ↗
  • Mehra N, Dolling D, Sumanasuriya S, Christova R, Pope L, Carreira S, Seed G, Yuan W, Goodall J, Hall E, Flohr P, Boysen G, Bianchini D, Sartor O, Eisenberger MA, Fizazi K, Oudard S, Chadjaa M, Mace S, de Bono JS. Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA). Eur Urol. 2018 Sep;74(3):283-291. doi: 10.1016/j.eururo.2018.02.013. Epub 2018 Feb 28. PubMed 29500065 ↗
  • Oudard S, Fizazi K, Sengelov L, Daugaard G, Saad F, Hansen S, Hjalm-Eriksson M, Jassem J, Thiery-Vuillemin A, Caffo O, Castellano D, Mainwaring PN, Bernard J, Shen L, Chadjaa M, Sartor O. Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. J Clin Oncol. 2017 Oct 1;35(28):3189-3197. doi: 10.1200/JCO.2016.72.1068. Epub 2017 Jul 28. PubMed 28753384 ↗
  • de Liano AG, Reig O, Mellado B, Martin C, Rull EU, Maroto JP. Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer. Br J Cancer. 2014 Apr 29;110(9):2201-8. doi: 10.1038/bjc.2014.189. Epub 2014 Apr 10. PubMed 24722180 ↗
  • Winquist E, Rodrigues G. Open clinical uro-oncology trials in Canada. Can J Urol. 2012 Dec;19(6):6587-91. No abstract available. PubMed 23228299 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2011 to primary completion in Sep 2015, 52 months.

Results were first posted in Mar 2017, 1 year 6 months after primary completion.

Of 126 industry-sponsored phase 3 interventional studies under Prostatic Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 53. This study's 52 months is above that.

Counting every sponsor, half of 265 studies reached it within 57 months; a quarter within 31 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2011
First posted
Mar 4, 2011
StartActual
May 5, 2011
Primary completionActual
Sep 2015
CompletionActual
May 2018
Results first posted
Mar 3, 2017
Last update
Jun 5, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 5, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01308567
Lead sponsor
Sanofi
Responsible party
Sponsor
First posted
Mar 4, 2011
Start date
May 5, 2011
Primary completion
Sep 2015
Completion
May 2018
Results posted
Mar 3, 2017
Last update
Jun 5, 2019

Study contacts

Clinical Sciences & Operations
study director · Sanofi

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cabazitaxel

Start the discussion